{
    "nctId": "NCT00193011",
    "briefTitle": "Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer",
    "officialTitle": "A Randomized Multicenter Trial Comparing Weekly Docetaxel and CMF in the Adjuvant Treatment of Women With High-Risk Breast Cancer Who Are > 65 Years Old or Are Not Candidates for Anthracycline-Based Adjuvant Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "disease-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\nTo be included in this study, you must meet the following criteria:\n\n* Female patients with adenocarcinoma of the breast confirmed by biopsy\n* Age 65 or older\n* Under age 65 must have significant medical illness, or general frailty\n* Adequate bone marrow, liver or kidney function\n* Normal heart function\n* Less than 84 days from mastectomy/lumpectomy or axillary dissection\n* Signed consent obtained prior to initiation of any study procedures\n\nExclusion Criteria:\n\nYou cannot participate in this study if any of the following apply to you:\n\n* Received neo-adjuvant therapy\n* Primary tumor is locally advanced at diagnosis\n* Received prior chemotherapy within five years\n* Received previous radiation therapy within 5 years\n* Peripheral neuropathy\n\nPlease note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}